Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of tolerance, suckling and food intake after repeated intranasal oxytocin in Prader-Willi syndrome infants
2012-005325-67Phase 2Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of oxytocin in Prader-Willi syndrome (PWS), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Primary safety endpoint. Started May 2022; status: active.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2012-005325-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005325-67.